• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline.
【24h】

Antimanic response to aripiprazole in bipolar I disorder patients is independent of the agitation level at baseline.

机译：双相I型障碍患者对阿立哌唑的抗躁狂反应与基线时的躁动水平无关。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To examine the antimanic efficacy of the relatively nonsedating antipsychotic aripiprazole in patients with bipolar I disorder and high or low baseline levels of agitation. METHOD: Data were pooled for this post hoc analysis from two 3-week, placebo-controlled trials of aripiprazole in acute mania (DSM-IV). Patients randomly assigned to aripiprazole 30 mg/day (N = 259) or placebo (N = 254) were classified as having either high (Positive and Negative Syndrome Scale [PANSS] Excited Component [PEC] score of >or=14 and a score of >or= 4 on at least one PEC item) or low (PEC < 14) levels of agitation at baseline. Efficacy measures were changes in Young Mania Rating Scale (YMRS) scores, Clinical Global Impressions-Bipolar (CGI-BP) scores, and PEC scores. Efficacy and agitation measurements were assessed by analysis of covariance. RESULTS: From the first week of therapy onward, aripiprazole-treated subjects had significantly greater reduction from baseline in YMRS total scores than placebo-treated subjects in both the high- and low-agitation groups (p < .05 for both groups) and significantly improved CGI-BP scores vs. placebo at end point (p < .05 for both). In highly agitated patients receiving aripiprazole, PEC scores were significantly decreased versus placebo at end point (p < .05). In patients with low agitation receiving aripiprazole, no increases in PEC scores were seen, and a significant reduction in agitation symptoms was apparent after adjustment for baseline PEC scores. CONCLUSIONS: Aripiprazole was superior to placebo in reducing the severity of both mania and agitation in highly agitated patients with bipolar I disorder and showed significant antimanic activity in patients with low levels of agitation without increasing agitation. These findings suggest that aripiprazole's antimanic effect is specific and not limited to control of agitation through sedation.
机译：目的：研究相对不镇定的抗精神病药物阿立哌唑对躁郁症I型患者和基线躁动程度高或低的患者的抗躁狂药疗效。方法：从两项为期3周的阿立哌唑在急性躁狂症（DSM-IV）的安慰剂对照试验中收集数据，用于事后分析。随机分配阿立哌唑30 mg / day（N = 259）或安慰剂（N = 254）的患者被分类为具有高（正负综合症量表[PANSS]兴奋成分[PEC]得分>或= 14并且得分为至少在一个PEC项目上大于或等于4）或基线时的搅拌水平低（PEC <14）。疗效指标包括年轻躁狂症评分量表（YMRS）得分，临床总体双相印象（CGI-BP）得分和PEC得分的变化。通过协方差分析评估功效和激动测量。结果：从治疗的第一周开始，在高和低激动度组中，阿立哌唑治疗的受试者的YMRS总得分较基线降低的幅度明显大于安慰剂治疗的受试者（两组的p <.05），并且显着与安慰剂相比，在终点时CGI-BP得分有所提高（两者均p <.05）。在服用阿立哌唑的情绪激动患者中，与安慰剂相比，PEC评分在终点显着降低（p <.05）。在接受阿立哌唑的低躁动患者中，PEC评分未见升高，调整基线PEC评分后，躁动症状明显减轻。结论：阿立哌唑在降低躁狂程度高的躁郁症患者中躁狂和躁动的严重程度方面优于安慰剂，在躁动程度低而不增加躁动的患者中表现出显着的抗躁狂活性。这些发现表明，阿立哌唑的抗躁狂作用是特异性的，并且不限于通过镇静来控制躁动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号